Most active: Novartis NOVN.SW (SIX) closed 19 Jan 2026: CHF115.56 outlook

NOVN.SW stock closed the Swiss SIX session at CHF115.56 on 19 Jan 2026 after trading 2,530,491.00 shares, keeping Novartis AG among the day’s most active names. The price finished within a CHF115.18–116.16 range and near its 52-week high of CHF116.78. Market participants focused on valuation and upcoming results with consensus earnings set for early February. We review intraday flows, valuation, technical signals and a model forecast to explain why Novartis (NOVN.SW) led activity on the SIX while markets were closed

NOVN.SW stock intraday summary and volume drivers

Novartis AG (NOVN.SW) ended the session at CHF115.56 on the SIX in Switzerland with volume 2,530,491.00 shares traded. The 1-day change was small at -0.04 CHF, but 1-month performance is strong at +6.49% and 1-year at +29.51%. Heavy ETF flows and rebalancing in Europe pushed liquidity; Bloomberg-listed Europe ETFs showed active trading that included Novartis positions source. We note the stock traded below the 50-day average price CHF107.80 earlier this period, then reclaimed higher levels into the close

Valuation snapshot: NOVN.SW stock vs sector

Novartis trades at PE 19.75 with EPS 5.85, placing it below the Swiss healthcare peer average PE of 33.79. Market cap sits around CHF221.74B. Price to sales is 4.90, price to book is 6.33, and dividend yield is 3.03% with payout ratio 0.54. The lower PE versus sector suggests valuation support despite a premium on book value. Investors weighing NOVN.SW stock see earnings stability and dividend income as offsets to higher price-to-book multiples

Financial and growth metrics for NOVN.SW stock

Novartis shows solid cash generation with free cash flow per share 9.39 and operating cash flow per share 10.82. Return on equity is elevated at 34.12%, and research intensity remains high with R&D at roughly 19.30% of revenue. Revenue growth for FY 2024 was 10.85%, while net income fell 19.59% year over year. Working capital is negative at -3802000000.00, reflecting industry dynamics in receivables and payables. These figures underline growth in operating cash flow and a mixed profit trend that traders track closely for the earnings announcement on 04 Feb 2026

Technical picture and Meyka AI grade for NOVN.SW stock

Momentum indicators show short-term strength: RSI 74.23 (overbought), MACD histogram 0.53, and ATR 1.69. The stock sits above its 50-day average CHF107.80 and 200-day average CHF99.73, supporting trend-following positions. Meyka AI rates NOVN.SW with a score of 75.11 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals warn of short-term overbought conditions while the grade highlights a constructive medium-term view

Catalysts, risks and sector context for NOVN.SW stock

Near-term catalysts include the earnings release scheduled for 04 Feb 2026 and trial readouts in Innovative Medicines. Key risks are generic pressure in Sandoz, patent cliffs and regulatory outcomes. Within Switzerland’s healthcare sector, Novartis sits alongside Roche and Abbott and shows stronger ROE but lower valuation than some peers. Macro risks such as FX and reimbursement trends remain relevant for NOVN.SW stock performance

Trading strategy and analyst price context for NOVN.SW stock

Active traders focused on NOVN.SW stock should watch support at CHF108.00 and near-term resistance at CHF116.78 (year high). A measured swing trade could use a stop near the 50-day average CHF107.80. Analysts’ consensus details are limited in public feeds, but model-based targets and sector comparisons suggest a balanced risk-reward. For more real-time metrics and alerts see the Meyka stock page for Novartis Novartis on Meyka and broader Europe ETF flows affecting the stock source.

Final Thoughts

NOVN.SW stock closed the SIX session on 19 Jan 2026 at CHF115.56 after heavy volume of 2,530,491.00 shares, making Novartis one of the market’s most active names. The company combines strong cash flow metrics and elevated ROE with a PE ~19.75, below the healthcare peer average. Short-term technicals show overbought readings, so momentum traders should monitor RSI and the CHF116.78 resistance. Meyka AI’s forecast model projects a 1-year price of CHF100.53, versus the current price CHF115.56, implying a -13.01% downside to that yearly target; longer-term (3-year) projection is CHF112.11, implying a smaller gap. Forecasts are model-based projections and not guarantees. Overall, our view frames NOVN.SW as a liquid, dividend-paying healthcare leader with defined catalysts ahead and a buy-graded medium-term profile from Meyka AI, while short-term traders should respect technical caution

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.